Recruiting

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Red River Research Partners, Fargo, North Dakota

Clinical Investigations of Texas, Dallas, Texas

Jordan

Triumpharma Clinical Research Unit at AlEssra Hospital, Amman, Jordan